

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Eptacog alfa

INITIATION

Prerequisites (tick box where appropriate)

- For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treating Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treating Group, subject to access criteria

HOSPITAL

I confirm that the above details are correct:

Signed: Date: